Lymphoid infiltration as a predictor of successful immunotherapy with melanoma
Cutaneous melanoma is 1-4% of all cancers. Among all malignant skin tumors, melanoma has a special place, it accounts for about 4% of all forms of skin cancer, but 80% of deaths in the group of malignant tumors of the skin caused by melanoma. In 2014 in Russian Federation, the standardized death rate from melanoma of the skin was 1.51 per 100 000 population. The incidence of melanoma has been steadily growing in Russian Federation and many other countries. In absolute increase the incidence of all malignant tumors, skin melanoma is ranked 2nd after lung cancer. Increased incidence of melanoma necessitates in-depth study of the biology of this tumor and its interaction with the immunobiological control system. Considering the immunogenicity of melanoma, the importance of the nature of the immune response to growing tumor. Therefore, one of the most important prognostic factor of the disease in these patients is the severity and subpopulations of lymphoid infiltration of the tumor, which is also important for the selection of personalized treatments with modern immunotherapeutic drugs, such as ipilimumab, which is the biological target for T cell suppressor receptor CTLA- 4.